Earlier this month, Surface Oncology shared that it will open a second stage of its monotherapy trial of SRF388, an antibody targeting IL-27, on the heels of a promising Phase 2 data readout. Shortly before that release, Business of Biotech caught up with Surface's CSO Vito Palombella, Ph.D., and CEO Rob Ross, M.D., in the company's Cambridge, MA, HQ.
|